AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 292 min read$ILMN

Illumina Non-GAAP EPS of $1.44 beats by $0.08, revenue of $1.13B misses by $20M (NASDAQ:ILMN)

Illumina reported Q3 Non-GAAP EPS of $1.44, exceeding estimates by $0.08, with revenue of $1.13B, missing by $20M. The company expects fiscal year 2026 revenue of $4.64B-$4.66B, excluding tariff refunds, according to a press release.

Original reporting
seekingalpha.com
Published Oct 29, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ILMN
Neutral
high confidence
Mentioned
$ILMN
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ILMNNeutralMed
01

Why it matters

The earnings beat may provide short‑term support, but the revenue miss and modest guidance could cap upside.

02

Market read

Earnings release provides fresh data for traders; mixed signals suggest cautious positioning.

03

What to watch

Potential impact of upcoming regulatory changes on sequencing pricing not reflected in the guidance.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Illumina's Q3 results were released via a press release on Oct 29, 2026.

Company-level read

Ticker impact

$ILMNNeutralHigh confidence
Context

Illumina reported Q3 Non‑GAAP EPS of $1.44, beating expectations by $0.08, while revenue of $1.13B missed by $20M and provided FY2026 revenue guidance of $4.64‑$4.66B.

Expected impact

mixed pressure as investors weigh the EPS beat against the revenue shortfall and modest guidance

Evidence & confidence

The surprise EPS beat may support the stock, but the revenue miss and guidance below consensus could limit upside.

Market effects

Sector

May influence other genomics and sequencing firms as investors compare earnings trends.

Regional

Primarily affects US biotech sector; limited broader market effect.

Global

Limited to investors tracking Illumina and related biotech stocks.

Counterpoint

What could challenge this read

The revenue miss could signal slowing demand, suggesting a short‑term pullback despite the EPS beat.

Key entities

  • company
    Illumina

    US‑listed genomics sequencing firm (NASDAQ:ILMN).

Read at source← All news

StoryIllumina posts Q3 FY2026 results, raises full‑year guidance but shares tumble

Also covered by

4 outlets

Related articles

OCT 29
$ILMNMedAI 8/10

Illumina Q3 Earnings Call Highlights

Illumina reported Q3 operating cash flow of $419M and free cash flow of $378M. The company raised its 2026 revenue outlook to $4.64B-$4.66B and expects full-year EPS of $5.40-$5.45. Q4 revenue is projected at $1.22B-$1.24B. Illumina placed over 80 NovaSeq X instruments in Q3, with high demand driven by clinical diagnostics. The company also highlighted its BioInsight ecosystem and AI data opportunities, with financial visibility expected in 2027.

finance.yahoo.com6 min
OCT 29
$AMZNHighAI 9/10

After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN

AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, and ILMN reported earnings after hours. AMZN missed Q3 estimates and guided Q4 below consensus. TWLO beat Q3 and raised FY2026 outlook but fell. INTC beat Q3 but guided Q4 below consensus. SNDK beat and raised Q1 guidance. RDDT and RBLX fell on cautious guidance. PINS missed Q3 and guided Q4 below consensus. RIVN beat Q3 and raised full-year guidance. SBUX posted mixed Q4 results. ILMN missed Q3 revenue.

investing.com6 min